Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

5.02EUR
12 Dec 2017
Change (% chg)

€0.42 (+9.13%)
Prev Close
€4.60
Open
€4.60
Day's High
€5.09
Day's Low
€4.58
Volume
587,326
Avg. Vol
288,414
52-wk High
€15.83
52-wk Low
€4.33

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.11
Market Cap(Mil.): €603.39
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Innate Pharma provides an update on lirilumab

* ‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS

22 Nov 2017

BRIEF-Innate Pharma Q3 revenue up at 12.4 million euros

* Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO

15 Nov 2017

BRIEF-Innate Pharma reports IPH4102 final results of the dose-escalation part of the phase I study

* IPH4102: FINAL RESULTS OF THE DOSE-ESCALATION PART OF THE PHASE I STUDY

16 Oct 2017

BRIEF-Innate Pharma H1 operating loss widens to 18.2 million euros

* ‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS() FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​

18 Sep 2017

BRIEF-New preclinical data further strengthen rationale of IPH5401 and Monalizumab

* REG-INNATE PHARMA : NEW PRECLINICAL DATA FURTHER STRENGTHEN THE RATIONALE OF IPH5401 AND MONALIZUMAB

11 Sep 2017

BRIEF-Innate Pharma issues 3,343,748 ordinary shares

* REG-ISSUANCE BY INNATE PHARMA OF 3,343,748 ORDINARY SHARES TO NOVO NORDISK A/S IN CONSIDERATION FOR RIGHTS IN ANTI-C5AR

13 Jul 2017

BRIEF-Innate Pharma to list 3,343,748 new ordinary shares - Euronext‍​

* INNATE PHARMA TO LIST 3,343,748 NEW ORDINARY SHARES AS OF JULY 17 FOLLOWING CAPITAL INCREASE BY CONTRIBUTION FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

13 Jul 2017

BRIEF-Innate Pharma dose-escalation data show favorable safety profile

* REG-INNATE PHARMA : DOSE-ESCALATION DATA SHOW FAVORABLE SAFETY PROFILE AND PROMISING CLINICAL ACTIVITY FOR IPH4102 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Jun 2017

Earnings vs. Estimates